Recursion Pharmaceuticals Reports 56% Revenue Decline and $117.5 Million Net Loss in Q1 2026

Recursion Pharmaceuticals, Inc. reported a significant decline in financial performance for the first quarter of 2026, with total revenue of $6.5 million, down 56% from $14.7 million in the same period last year. The decrease was primarily attributed to reduced revenue from strategic partnerships, particularly with Roche, as certain project phases were completed in the prior year. The company incurred a net loss of $117.5 million, a 42% improvement compared to the net loss of $202.5 million reported in the first quarter of 2025. This reduction in losses was driven by a decrease in operating costs, which fell by 35% to $135 million, reflecting strategic cost management and operational efficiencies.

In terms of operational developments, Recursion's total operating expenses decreased significantly, with research and development costs dropping by 32% to $87.9 million, and general and administrative expenses decreasing by 37% to $34.6 million. The company attributed these reductions to a strategic reprioritization of its clinical portfolio and a decrease in headcount. As of March 31, 2026, Recursion had cash, cash equivalents, and restricted cash totaling $665.2 million, down from $753.9 million at the end of 2025, indicating a continued need for capital to support ongoing operations and development efforts.

Recursion has made notable strides in its drug development pipeline, with several key programs advancing. The company reported favorable preliminary safety and pharmacokinetic data for REC-1245, a potential cancer treatment, and has initiated clinical studies for REC-4539, an LSD1 inhibitor. The company also continues to engage in strategic partnerships, having received over $500 million in milestone and upfront payments to date. These collaborations are expected to drive future revenue growth as the company progresses toward potential commercialization of its drug candidates.

Looking ahead, Recursion anticipates the need for additional financing to support its operations and drug development initiatives. The company has entered into a new sales agreement with TD Securities to raise up to $300 million through at-the-market offerings, although no shares have been sold under this agreement as of the reporting date. Recursion's management believes that its existing cash reserves will be sufficient to fund operations for at least the next 12 months, but acknowledges the ongoing risks associated with the biotechnology industry, including the uncertainty of clinical trial outcomes and the need for continued capital investment.